Celgene Corporation (NASDAQ:CELG) Shares Bought by Peregrine Capital Management LLC
Peregrine Capital Management LLC boosted its stake in shares of Celgene Corporation (NASDAQ:CELG) by 9.6% during the second quarter, Holdings Channel reports. The firm owned 154,786 shares of the biopharmaceutical company’s stock after buying an additional 13,571 shares during the period. Peregrine Capital Management LLC’s holdings in Celgene Corporation were worth $20,102,000 at the end of the most recent quarter.
Several other institutional investors have also recently modified their holdings of the stock. Kentucky Retirement Systems Insurance Trust Fund purchased a new position in shares of Celgene Corporation during the fourth quarter valued at about $2,905,000. Kentucky Retirement Systems purchased a new position in shares of Celgene Corporation during the fourth quarter valued at about $6,511,000. Teachers Advisors LLC boosted its position in shares of Celgene Corporation by 23.0% in the fourth quarter. Teachers Advisors LLC now owns 2,102,104 shares of the biopharmaceutical company’s stock valued at $243,319,000 after buying an additional 393,395 shares during the period. Garde Capital Inc. purchased a new position in shares of Celgene Corporation during the fourth quarter valued at about $201,000. Finally, Perigon Wealth Management LLC boosted its position in shares of Celgene Corporation by 16.6% in the fourth quarter. Perigon Wealth Management LLC now owns 46,254 shares of the biopharmaceutical company’s stock valued at $5,720,000 after buying an additional 6,578 shares during the period. Institutional investors own 78.39% of the company’s stock.
Shares of Celgene Corporation (CELG) traded up 0.59% during trading on Friday, reaching $136.70. The company had a trading volume of 3,197,673 shares. The company has a market cap of $106.95 billion, a price-to-earnings ratio of 42.34 and a beta of 1.89. The firm has a 50 day moving average price of $132.00 and a 200 day moving average price of $123.32. Celgene Corporation has a 12 month low of $96.93 and a 12 month high of $139.00.
Celgene Corporation (NASDAQ:CELG) last announced its earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.82 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.61 by $0.21. Celgene Corporation had a net margin of 21.35% and a return on equity of 68.51%. The company had revenue of $3.27 billion for the quarter, compared to analysts’ expectations of $3.23 billion. During the same period last year, the firm earned $1.44 earnings per share. The business’s revenue for the quarter was up 18.7% on a year-over-year basis. Analysts predict that Celgene Corporation will post $7.32 earnings per share for the current year.
TRADEMARK VIOLATION NOTICE: “Celgene Corporation (NASDAQ:CELG) Shares Bought by Peregrine Capital Management LLC” was originally reported by Daily Political and is the sole property of of Daily Political. If you are reading this article on another site, it was illegally copied and republished in violation of US and international copyright and trademark law. The correct version of this article can be viewed at https://www.dailypolitical.com/2017/08/05/celgene-corporation-nasdaqcelg-shares-bought-by-peregrine-capital-management-llc.html.
Several brokerages have recently issued reports on CELG. Mizuho set a $134.00 price target on Celgene Corporation and gave the company a “buy” rating in a research report on Wednesday, July 26th. Cantor Fitzgerald set a $160.00 price target on Celgene Corporation and gave the company a “buy” rating in a research report on Thursday, July 27th. Robert W. Baird reiterated an “outperform” rating and set a $162.00 price target on shares of Celgene Corporation in a research report on Friday, July 21st. Jefferies Group LLC reiterated a “buy” rating and set a $160.00 price target on shares of Celgene Corporation in a research report on Monday, July 31st. Finally, Cann reiterated a “buy” rating and set a $175.00 price target on shares of Celgene Corporation in a research report on Tuesday. One analyst has rated the stock with a sell rating, six have issued a hold rating and twenty-three have issued a buy rating to the company. The company has an average rating of “Buy” and an average price target of $147.06.
In other news, insider Rupert Vessey sold 4,785 shares of the firm’s stock in a transaction that occurred on Thursday, June 15th. The shares were sold at an average price of $120.18, for a total transaction of $575,061.30. Following the transaction, the insider now directly owns 4,004 shares of the company’s stock, valued at $481,200.72. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Michael D. Casey sold 9,250 shares of the firm’s stock in a transaction that occurred on Monday, June 19th. The stock was sold at an average price of $125.59, for a total transaction of $1,161,707.50. The disclosure for this sale can be found here. Insiders have sold 235,255 shares of company stock worth $31,377,042 over the last ninety days. Insiders own 0.95% of the company’s stock.
About Celgene Corporation
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Corporation (NASDAQ:CELG).
Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.